[Federal Register Volume 64, Number 93 (Friday, May 14, 1999)]
[Notices]
[Pages 26421-26422]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 99-12204]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Government-Owned Inventions; Availability for Licensing

AGENCY: Centers for Disease Control and Prevention (CDC), Department of 
Health and Human Services (DHHS).

ACTION: Notice.

-----------------------------------------------------------------------

    The inventions named in this notice are owned by agencies of the 
United States Government and are available for licensing in the United 
States (U.S.) in accordance with 35 U.S.C. 207 to achieve expeditious 
commercialization of results of federally funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for U.S. companies and may also be 
available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by writing to Thomas E. 
O'Toole, M.P.H., Deputy Director, Technology Transfer Office, Centers 
for Disease Control and Prevention (CDC), Mailstop E-67, 1600 Clifton 
Rd., Atlanta, GA 30333, telephone (404) 639-6270; facsimile (404) 639-
6266. Please note that a signed Confidential Disclosure Agreement will 
be required to receive copies of the patent applications.

Oligonucleotide Probes for Detecting Enterobacteriaceae and 
Quinolone-ResistantEnterobacteriaceae

    Specific oligonucleotide probes have been developed to be 
incorporated into methods for the species-specific identification of 
these Enterobacteriaceae in a sample as well as detection and diagnosis 
of Enterobacteriaceae infection in a subject. This invention further 
provides methods for species-specific identification of these 
quinolone-resistant Enterobacteriaceae as well as the detection and 
diagnosis thereof.

Inventor: Linda M Weigel, et al.
U.S. Patent Application SN: 60/080,375 (CDC Ref. #: I-003-98/0)

Compositions and Methods for Detecting Adult Taenia Solium

    Compositions and methods for the detection of adult Taenia solium 
and the diagnosis and treatment of T. solium infection are described. 
The compositions contain one or more adult T. solium polypeptides which 
can be useful as diagnostic agents for the detection of adult tapeworm 
infection.

Inventor: Victor Tsang, et al.
U.S. Patent Application SN: 60/111,334 (CDC Ref. #: I-028-97/0)

Recombinant Multi-Valent Malarial Vaccine

    This invention relates generally to the development and use of a 
recombinant, multi-valent and multi-stage malaria vaccine and more 
specifically relates to an antigenic protein useful for preventing or 
treating P. falciparum malarial infections. The invention further 
provides a vaccine against malaria that is effective in inhibiting 
reproductive growth of the parasite within a human or animal after 
initial infection. Also, this invention provides a method for 
conferring immunity against different stages in the life cycle of the 
malarial parasite, P. falciparum. Furthermore, the invention includes 
antibodies against a recombinant protein containing antigenic epitopes 
to various stages of a malarial Plasmodium species that may be useful 
as research or diagnostic reagents for the detection and measurement of 
P. falciparum in a biological sample.

Inventor: Altaf A. Lal, et al.
U.S. Patent Application SN: 60/097,703 (CDC Ref. #: I-004-98/0)

Reagent and Method for Detecting Cryptosporidium Parvum Oocysts

    A reagent and method for the specific and highly sensitive 
detection of C. parvum in which the reagent is an antibody for a 
soluble C. parvum sporozoite antigen. The method comprises of an 
immunoassay in which the antibody is used to detect or quantify C. 
parvum sporozoite in a sample. The assay allows recognition and 
detection of C. parvum in turbid samples. And since there exists a lack 
of crossreactivity with other Cryptosporidium species, the assay is 
also highly specific for C. parvum contamination or infection.

Inventor: Victor Tsang, et al.
U.S. Patent Application SN: 60/111,225 (CDC Ref. #: I-039-98/0)

Isolation of a New Human Retrovirus

    A new isolate of a human retrovirus has been identified in several 
cases of foamy virus infection in persons at risk for this occupational 
exposure to simian retroviruses. This new isolate demonstrates a number 
of phenotypic differences from previously isolated foamy viruses by its 
immune reactivity, cell tropism, cytopathcity and growth kinetics. Due 
to its human-derived/adapted nonpathogenic nature, this new isolate may 
be suitable as a potential gene therapy vector.

Inventor: Paul A. Sandstrom
U.S. Patent Application SN: 60/105,811 (CDC Ref. #: I-034-97/0)

Methods and Compositions for the Detection of Human Herpesvirus

    Methods and compositions for the detection and diagnosis of 
infectious diseases are provided. In particular, efficient and 
sensitive compositions and methods for the detection of human 
herpesvirus 8 are provided. The diagnostic compositions and methods of 
the invention involve the use of peptides representative of dominant 
antigenic regions of human herpesvirus in detection assays. Such assays 
are highly specific, sensitive and accurate.

Inventor: Chou-Pong Pau
U.S. Patent Application SN 60/086,695 (CDC Ref. #: I-018-98/0)

Methods and Reagents for Molecular Detection of HIV-1 Groups M, N, 
and O

    This invention provides reagents and assays for detecting HIV-1 
groups M and O and optionally HIV-1 group N and SIVcpz. Nucleic acid 
primers for the hybridization to, amplification and subsequent 
detection are also provided for. The nucleic acid amplification assays 
can detect small concentrations of HIV and are also useful for 
qualitative and quantitative examinations.

Inventor: Renu B. Lal, et al.
U.S. Patent Application SN: 60/118,357 (CDC Ref. #: I-020-98/0)

Nucleic Acid Vaccines for the Prevention of Flavivirus Infection

    This novel vaccine for flaviviruses comprises of recombinant 
nucleic acids that contain genes for structural proteins of 
flaviviruses, such as Japanese encephalitis virus (JEV). These vaccines 
serve as a transcriptional unit for the biosynthesis of the virus 
protein antigens when administered in vivo. Furthermore, the invention 
provides for a method of immunizing a subject against infection by a 
flavivirus.


[[Page 26422]]


Inventor: Gwong-Jen J. Chang
U.S. Patent Application SN: 60/087,908 (CDC Ref. #: I-008-97/0)

Method and Devices for Detection of Retroviral Infection

    This invention comprises of methods, devices and compositions for 
detection of endogenous retroviruses found in xenotransplant materials. 
The methods and compositions are suited for detection of endogenous 
type-C retroviruses and in particular, for porcine endogenous 
retrovirus (PERV). Detection of such is necessary following 
xenotransplantation of porcine cellular products.

Inventor: Walid Heneine, et al.
U.S. Patent Application SN 60/090,972 (CDC Ref. #: I-021-98/0)

Methods and Devices for Detection of Xenogeneic Infectious Agents

    Compositions, methods and diagnostic devices for monitoring porcine 
graft integrity and detecting the presence of porcine endogenous 
retrovirus (PERV) in a biological sample. The compositions, methods and 
devices are useful for determining or monitoring graft survival and 
rejection in recipients of xenografts and are useful for detecting PERV 
infections in a xenotransplant recipient or donor. In addition, the 
compositions, methods and devices are useful for screening therapeutic 
products to be administered to humans to ensure that the products are 
free of PERV contamination prior to administration.

Inventor: Bill Switzer, et al.
U.S. Patent Application SN: 60/093,202 (CDC Ref. #: I-024-98/0)
Associated U.S. Patent Application SN: 60/098,262 (CDC Ref. #: I-024-
98/1)

Methods for the Prevention and Treatment of Diseases Caused by an 
Inflammatory Response

    This invention provides methods for preventing or treating a 
disease in a subject caused by an inflammatory response to a disease or 
syndrome that is mediated by endogenous substance P. The methods 
include administration of anti-substance P antibodies or anti-substance 
P antibody fragments.

Inventor: Ralph A. Tripp, et al.
U.S. Patent Application SN: 60/116,835 (CDC Ref. #: I-009-98/0)
    13

Preparation and Use of Recombinant Influenza A Virus M2 Constructs 
in Vaccines

    M2, a structurally conserved influenza A viral surface protein, is 
capable of inducing broader, more cross-reactive immunity to type A 
influenza viruses. This invention solves the problems of the prior art 
approaches to recombinant M2 production by providing new recombinant 
forms of M2 whose structure has been modified to allow simple 
prokaryotic expression as a soluble, readily purified variant protein 
which retains antigenic and immunogenic properties. The invention 
relates to vaccines comprised of these new recombinant forms of M2, and 
to methods of prevention and treatment of influenza A virus infections.

Inventor: A. Michael Frace, et. al.
U.S. Patent Application SN: 08/906,930 (CDC Ref. #: I-020-97/0)

Method and Kit for Detecting Resistance to Antiviral Drugs

    One of the problems with the development of current therapies for 
HIV infection is that the HIV virus rapidly develops resistance to 
drugs such as reverse transcriptase inhibitors. This invention provides 
for an assay and kit for the detection of phenotypic resistance to a 
reverse transcriptase inhibitor drug in a biological sample.

Inventor: Walid Heneine, et al.
U.S. Patent Application SN: 60/090,051 (CDC Ref. #: I-005-98/0)

Novel Granulocytic Ehrlichia Genes and Uses Thereof

    Granulocytic ehrlichiosis is an acute, potentially fatal tick-borne 
infection. This invention provides for granulocytic ehrlichia specific 
genes encoding thirteen proteins that can be used as diagnostic 
reagents and vaccines. Isolated nucleic acid molecules, purified 
polypeptides, nucleic acid probes, and antibodies to the thirteen 
proteins are provided for. The recombinant nucleic acid molecule, 
vectors, cells and many other forms of the molecule are provided for 
along with the methods and kit for detection.

Inventor: Cheryl I. Murphy, et al.
U.S. Patent Application SN: 09/178,316 (CDC Ref. #: I-011-99/0)

Invasion Associated Genes from Neisseria Meningitidis Serogroup B

    The invention provides nucleic acids and encoded polypeptides 
associated with invasion of Neisseria meningitidis. The polypeptides 
are used as diagnostic reagents, as immunogenic reagents, and as 
components of vaccines. The nucleic acids are used as diagnostic 
reagents, as components of vectors and vaccines, and to encode the 
polypeptides of the invention. The invention also provides strains of 
Neisseria meningitidis which have an invasion deficient phenotype.

Inventors: Frederick D. Quinn, et. al.
U.S. Patent Application SN: 60/030,432 (Ref. #: I-002-95/0)

    Dated: May 10, 1999.
Joseph Carter,
Acting Associate Director for Management and Operations, Centers for 
Disease Control and Prevention (CDC).
[FR Doc. 99-12204 Filed 5-13-99; 8:45 am]
BILLING CODE 4163-18-P